Moreover, a subanalysis of the EARTH EXPLORER 2 trial, conducted to dissect whether mavrilimumab and golimumab (TNF inhibitor) in both conventional DMARDs and TNF‐inhibitor inadequate responder RA patients may differ in the modulation of peripheral biomarkers and pathophysiological pathways, showed that serum levels of CCL22 and CCL17 were suppressed selectively by mavrilimumab but not golimumab, while CXCL13 and ICAM1 levels were suppressed by golimumab but not mavrilimumab. The gene discussed is TNF; the disease is rheumatoid arthritis.